Show Notes
<p>Host: Richard Young, VP, Strategy, Veeva Vault CDMS</p> <p>Guest: Rhona O’Donnell, VP, Data Management Systems and Standards, Novo Nordisk</p> <p>This week, Richard Young is joined by Rhona O’Donnell, VP, Data Management Systems and Standards at Novo Nordisk. They discuss the evolution of the data management role, and how we can prepare for the future through collaboration and more effective training for the next generation. Richard and Rhona share their thoughts on the growing list of responsibilities facing data managers; why risk-based data management can help make trials more sustainable; the largest opportunities for time savings within the data management world; and the big initiatives that Novo Nordisk is working on to improve their data management processes. </p> <p>Get in touch with us if you would like to contribute to the podcast or share your feedback [email protected]</p> <p>Subscribe to State of Digital Clinical Trials, a Veeva podcast to get new episodes as soon as they are released.</p> <p>Spotify:<a href="https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbF9PS2YwUUZTWjZoWmllNF9TN2FvZGEwUEVBd3xBQ3Jtc0ttd0dkLTAzOW5laHloOTEwX1RTSEVuMXREc2tGMXVUTjdiTmpnMzJMbUYxZTZZUS1fUERLclhoeHIwUWRORVJXd0tjVTVHSlZ4Z1pxbWtFNmVHaGxpWlpRaUROYVprb3BmSHk0MkZoOW9ac0ctMk40QQ&q=https%3A%2F%2Flnkd.in%2Fe5pJ7saP&v=Gc2-0nHtUC4"> https://lnkd.in/e5pJ7saP</a></p> <p>Youtube:<a href="https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqa1hwSWJNRjFEbFVVWlpDM2ltR3NfM3BKb2FzUXxBQ3Jtc0ttTUVKN2JBelZIX3BudUlvYnhObzR0Y1NFS2FhZV9uM3ZFTzE5UEsxcV9GZHY1QWNTRTQxMjJZS09wRlJaT0ZRU214UXFCYkRJUXFsUjhBN2dleDBXRTR2WnJBRFh1SGEtb2JpbUVtZGsyRzlIaXRRcw&q=https%3A%2F%2Fbit.ly%2F3quY9FY&v=Gc2-0nHtUC4"> https://bit.ly/3quY9FY</a></p> <p>Apple Podcasts:<a href="https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqblp3bHpKcmVDVmNzTEN0aHB2M3ZXRjJ2bFYwQXxBQ3Jtc0tuWHU0ZFR1UnFDR0Fka25PMGRaWXRPTzhlQnQzd0pfeDlpRlBNRDhua1FRSVV2OFBGQzBmR2lzMHY5Q3FCcV95S2FzSjFJM2RmN3hsTFB6emN4MFBSYWIxZjdZdVM2QkVJeFJUUk5iWksyR2VQT3dRWQ&q=https%3A%2F%2Flnkd.in%2FefMTxybk&v=Gc2-0nHtUC4"> https://lnkd.in/efMTxybk</a></p> <p><br></p>
More from Unblinded: A Clinical Trial Podcast
Manny is joined by guest Jack Evans, VP Europe at Civia Health, to discuss the operational realities, systemic burdens, and collaborative opportunities between clinical trial sponsors, CROs, and research sites. Jack highlights the challenges of setting up a research site in Europe, and what they need from sponsors to help make clinical trials more efficient.
In this episode Danielle Drachmann, CEO of Ketotic Hypoglycemia International, and Senior Patient Partnering Manager at Thermo Fisher Scientific, explains how lived experience can – and should – reshape clinical research from day one. Danielle shares her powerful personal journey from kindergarten teacher to founder of a global rare disease organization after fighting for answers for her children.
In this episode, Novo Nordisk’s Rhona O'Donnell and Ibrahim Kamstrup-Akkaoui explore how the combination of open source tools and AI is reshaping the future of clinical data management. From the creation of OpenStudyBuilder to the potential of Veeva’s agentic AI layer, they discuss breaking down traditional industry silos to get treatments to patients faster.
In this episode of Unblinded, host Manny Vazquez is joined by Leianne Ebert, Head of Data Operations at Alcon, and co-host John Acampado, Senior Director of Clinical Strategy for Veeva MedTech. Together, they explore the regulatory differences between pharma and medical device trials, data standards, and the industry’s digital maturity. Leianne and John also provide a reality check on AI readiness, debating the "deep pockets, short arms" mentality of the industry, and end with a call to action for systemic technology adoption.
Joel White, owner of Marketcap Consulting, together with Veeva’s Chris Kreitel, joins Manny to discuss why the next era of clinical trial outsourcing will be defined by technology integration and economic agility. They debate whether CROs are the ultimate masters of integrating tech, and the role of small biotechs as growth drivers in the market.